Title |
The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines
|
---|---|
Published in |
BMC Research Notes, June 2012
|
DOI | 10.1186/1756-0500-5-274 |
Pubmed ID | |
Authors |
Diozele Hazel M Sanvictores, Marilla G Lucero, Hanna Nohynek, Veronica L Tallo, Antti Tanskanen, Leilani T Nillos, Gail Williams, and the ARIVAC Consortium |
Abstract |
A large phase III placebo-controlled, randomized efficacy trial of an investigational 11-valent pneumococcal conjugate vaccine against pneumonia in children less than 2 years of age was conducted in the Philippines from July 2000 to December 2004. Clinical data from 12,194 children who were given either study vaccine or placebo was collected from birth up to two years of age for the occurrence of radiologically proven pneumonia as the primary endpoint, and for clinical pneumonia and invasive pneumococcal disease as the secondary endpoints. Several tertiary endpoints were also explored. Along the core trial, several satellite studies on herd immunity, cost-effectiveness of the study vaccine, acute otitis media, and wheezing were conducted. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 3% |
Belgium | 1 | 1% |
Unknown | 74 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 16 | 21% |
Student > Master | 15 | 19% |
Student > Ph. D. Student | 12 | 16% |
Other | 6 | 8% |
Student > Postgraduate | 5 | 6% |
Other | 11 | 14% |
Unknown | 12 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 28 | 36% |
Nursing and Health Professions | 6 | 8% |
Economics, Econometrics and Finance | 5 | 6% |
Agricultural and Biological Sciences | 4 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Other | 16 | 21% |
Unknown | 14 | 18% |